Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

This study investigates whether the time of day when chemotherapy and immunotherapy (pembrolizumab) is given affects how well the treatment works for triple-negative breast cancer (TNBC). Our body follows a natural 24-hour internal clock called the circadian rhythm, which influences how cells respond to drugs. Researchers believe that delivering cancer treatment at the right time of day may improve how tumors respond and reduce side effects — a growing field called chronotherapy. **You may be eligible if:** - You are female between 18 and 75 years old - You have been diagnosed with Stage II or III triple-negative breast cancer (confirmed by biopsy) - Your care team has recommended pre-surgery chemotherapy combined with pembrolizumab (immunotherapy) as part of your treatment plan - You are enrolled in a social health protection scheme **You may NOT be eligible if:** - You are pregnant or breastfeeding - You are unable to understand or consent to the study - You are not a candidate for the planned neoadjuvant (pre-surgery) treatment - You have medical contraindications to the study treatment Talk to your doctor to see if this trial is right for you.